Answers are grounded in this paper and cite their sources.
Background: Acromegaly is a rare endocrine disorder, most commonly caused by a growth hormone (GH)–secreting pituitary adenoma. This study aimed to assess circulating β-catenin protein levels in patients with acromegaly and to compare its diagnostic performance with routine laboratory tests.Methods: This case–control study included 60 adults with acromegaly and 30 age- and sex-matched healthy subjects (HS). Fasting blood glucose, lipid profile, renal and liver function tests, GH, insulin-like growth factor-1 (IGF-1), uric acid, and β-catenin were measured in all participants.Results: β-catenin levels were significantly higher in patients with acromegaly than in HS. Receiver operating characteristic (ROC) curve analysis demonstrated excellent discriminatory ability of β-catenin for acromegaly, with an area under the curve (AUC) of 0.992 (p < 0.001). At an optimal cutoff value of > 1.811, the sensitivity was 91.7%, and the specificity was 100%. DeLong’s test further confirmed the superior diagnostic performance of β-catenin compared with routine tests. Correlation analysis showed that β-catenin was significantly and positively correlated with IGF-1, total cholesterol, and total serum bilirubin (TSB), while it was significantly and negatively correlated with creatinine. Multiple linear regression identified IGF-1, GH, urea, GPT, ALP, TSB, and uric acid as independent predictors of β-catenin levels.Conclusion: β-catenin levels are elevated in patients with acromegaly and exhibit excellent diagnostic performance. Monitoring β-catenin may provide clinically useful information and could assist in risk stratification and management of acromegaly.
No takes yet. Share an insight, caveat, or question.
Abed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: